Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2021

In 2021, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 21.34% of shares outstanding on 15 Jan 2021 to 34.02% on 31 Dec 2021, a change of +12.68 percentage points. The year's high was 34.02% on 31 Dec 2021 and its low 8.61% on 31 Mar 2021, averaging 16.95% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.24 days on 15 Dec 2021. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2021

2021 in figures

Start of year
21.34% (15 Jan 2021)
End of year
34.02% (31 Dec 2021)
Change
+12.68 pp
High
34.02% (31 Dec 2021)
Low
8.61% (31 Mar 2021)
Average
16.95%
Highest days to cover
5.24 (15 Dec 2021)
SEC filings marked
8

Every report in 2021

FILANA THERAPEUTICS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202121.34%1.34
29 Jan 202123.38%1.57
12 Feb 202110.24%1.00
26 Feb 202111.49%1.00
15 Mar 202114.27%1.60
31 Mar 20218.61%1.4310-K filed, results (8-K)
15 Apr 20219.10%3.30
30 Apr 20219.41%2.24results (8-K), 10-Q filed
14 May 20218.69%4.02
28 May 20219.47%2.27
15 Jun 20219.42%1.32
30 Jun 20219.92%1.32
15 Jul 202111.08%1.46
30 Jul 202110.02%1.00
13 Aug 202113.50%1.00results (8-K), 10-Q filed
31 Aug 202119.74%1.00
15 Sep 202122.19%1.00
30 Sep 202121.92%1.00
15 Oct 202123.54%2.53
29 Oct 202128.36%3.95
15 Nov 202120.95%1.00results (8-K), 10-Q filed
30 Nov 202125.60%2.31
15 Dec 202130.45%5.24
31 Dec 202134.02%3.00

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.